Skip to content
ZA 4610mg

Drawing based on the label description. No photo yet.

ZA 46 10mg pill

Pill with imprint ZA 46 10mg is blue & white, capsule, 14 mm and has been identified as Ramipril 10 mg. It is used for high blood pressure, heart failure and a weak heart. It is supplied by Zydus Lifesciences Limited.

Ramipril 10 mg

Imprint
ZA 46 10mg
Strength
10 mg
Used for
High blood pressure, heart failure and a weak heart
Color
Blue, White
Shape
Capsule / oblong
Size
14 mm
Score
No score line
Form
Capsule
Manufacturer
Zydus Lifesciences Limited
Drug class
ACE inhibitor (blood pressure and heart medicine)
NDC
65841-658, 65841-658-06, 65841-658-16, 65841-658-01, 65841-658-05, 65841-658-30, 68382-147, 68382-147-06, 68382-147-16, 68382-147-01, 68382-147-05, 68382-147-30, 68382-147-77

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Ramipril pills and guides

What is Ramipril used for?

Ramipril is used for high blood pressure, heart failure, a weak heart and kidney disease from diabetes.

Medicine type
ACE inhibitor (blood pressure and heart medicine)
Official uses from the US prescribing label

Hypertension

Ramipril capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

Ramipril capsules may be used alone or in combination with thiazide diuretics.

Reduction in the Risk of Myocardial Infarction, Stroke, and Death from Cardiovascular Causes

Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, anti-platelet, or lipid-lowering therapy).

Heart Failure Post-Myocardial Infarction

Ramipril capsules are indicated in stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of ramipril capsules to such patients have been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risks of failure-related hospitalization and progression to severe/resistant heart failure.

From the FDA-approved label on DailyMed (published Sep 29, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • Your pill shows ZA 46 10mg. The parts can be split between the two sides, so turn the pill over and check both.
  • It is blue & white, capsule, 14 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Ingredients

Active: Ramipril

Inactive: D&c Red No. 28, D&c Yellow No. 10, Fd&c Blue No. 1, Gelatin, Titanium Dioxide, Starch, Corn, Ferrosoferric Oxide

Also distributed by

Zydus Pharmaceuticals USA Inc.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Ramipril pills